Literature DB >> 8532599

Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract.

A Fjellestad-Paulsen1, C Söderberg-Ahlm, S Lundin.   

Abstract

The bioavailability from the gastrointestinal tract of peptides as large as nonapeptides is very low, which may be attributed to extensive lumenal and mucosal degradation. The aim of the present study was to investigate the stability of the neurohypophyseal hormones arginine-vasopressin (AVP), oxytocin (OT), and their synthetic analogues in human intestinal contents, small intestinal brush-border membranes, and gastric, rectal, and colonic plasma membranes. Peptides were incubated in gastrointestinal contents from healthy volunteers and in human intestinal mucosa homogenates. The extent of degradation was determined by reversed-phase high performance liquid chromatography (HPLC). AVP was rapidly degraded in the ileum fractions of the intestinal contents whereas 50% of the analogue 1-deamino-8-D-arginine vasopressin (dDAVP) remained intact after 35 min. The degradation was pH dependent, and a concentration-dependent inhibition was observed when aprotinin, a proteinase inhibitor, was preincubated with contents from the ileum. No degradation of AVP, dDAVP, or oxytocin analogues was observed in the mucosa homogenate from the stomach. The peptides were found to be rather slowly degraded by intestinal microvilli membranes and colonic and rectal plasma membranes. This degradation occurred essentially when reduced glutathione 10(-4) M was added to the incubations. In conclusion, the major enzymatic barrier to intestinal absorption of OT, VP, and their analogues is present in the intestinal juice and not in the mucosa, which, however, constitutes a major physical barrier to peptide transport.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8532599     DOI: 10.1016/0196-9781(95)00088-2

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  7 in total

Review 1.  A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research.

Authors:  Marilena M DeMayo; Yun Ju C Song; Ian B Hickie; Adam J Guastella
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

2.  WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action.

Authors:  Callum Hicks; Linnet Ramos; Tristan A Reekie; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

Review 3.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

4.  Associations Between Nurse-Guided Variables and Plasma Oxytocin Trajectories in Premature Infants During Initial Hospitalization.

Authors:  Ashley Weber; Tondi M Harrison; Loraine Sinnott; Abigail Shoben; Deborah Steward
Journal:  Adv Neonatal Care       Date:  2018-02       Impact factor: 1.968

5.  On the Utility of Chemical Strategies to Improve Peptide Gut Stability.

Authors:  Thomas Kremsmayr; Aws Aljnabi; Juan B Blanco-Canosa; Hue N T Tran; Nayara Braga Emidio; Markus Muttenthaler
Journal:  J Med Chem       Date:  2022-04-14       Impact factor: 8.039

6.  Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide.

Authors:  Maria Giulia Di Giglio; Markus Muttenthaler; Kasper Harpsøe; Zita Liutkeviciute; Peter Keov; Thomas Eder; Thomas Rattei; Sarah Arrowsmith; Susan Wray; Ales Marek; Tomas Elbert; Paul F Alewood; David E Gloriam; Christian W Gruber
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

7.  Effect of oxytocin injection to milching buffaloes on its content & stability in milk.

Authors:  Raghu Pullakhandam; Ravindranadh Palika; Sudershan Rao Vemula; Kalpagam Polasa; Sesikeran Boindala
Journal:  Indian J Med Res       Date:  2014-06       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.